Litcius/Paper detail

Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma

Steven Powell, Miroslaw Mazurczak, Elie G. Dib, Jonathon S. Bleeker, L. Geeraerts, Matthew Tinguely, Michele Lohr, Steven McGraw, Ashley W. Jensen, Christie Ellison, Lora Black, Susan E. Puumala, Valerie Reed, W. Keith Miskimins, John H. Lee, William C. Spanos

2022Investigational New Drugs57 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboInternal medicineHead and neck squamous-cell carcinomaAdverse effectChemoradiotherapyClinical endpointGastroenterologyToxicityHead and neck cancerLactate dehydrogenasePharmacologyChemotherapyOncologyRadiation therapyRandomized controlled trialPathologyBiologyAlternative medicineBiochemistryEnzymeCancer, Hypoxia, and MetabolismLung Cancer Research StudiesHead and Neck Cancer Studies
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma | Litcius